Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will extend Business Rates reimbursements to Community Pharmacies.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
In the 2025 Autumn Budget, the Government took the hard choices to protect the National Health Service in England and to continue to prioritise reducing waiting times. We have also stepped in to cap bills and help businesses, as part of a £4.3 billion support package.
This year, we have also increased funding to community pharmacies to almost £3.1 billion, the largest uplift in funding for any part of the NHS across 2024/25 and 2025/26.
The Department will consult Community Pharmacy England on any proposed changes to reimbursement and remuneration of pharmacy contractors for 2026/27 shortly.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how organisations providing mental health services to children and young people can engage with the Independent review into mental health conditions, ADHD and autism.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
My Rt. Hon. Friend, the Secretary of State for Health and Social Care, has launched an independent review into prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD) and autism. We are deeply concerned that many adults, young people and children with mental health conditions, ADHD and autism have been let down by services and are not receiving timely or appropriate support and treatment. This Government has already taken significant steps to stabilise and improve NHS mental health services but there is much more to do. Transforming the system will take time, but we are committed to delivering a new approach to mental health.
Therefore, this independent review will inform our new approach to mental health, so people receive the right support, at the right time and in the right place. Likewise, the review will inform our approach so that people with ADHD and autistic people have the right support in place to enable them to live well in their communities.
As this is an independent review, it is for the Chair and Vice-chairs to consider who to consult and the relevant forums for engagement, that are relevant to deliver the terms of reference, set by the Department.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his department are taking steps to support the use of the Play Well Toolkit in NHS healthcare settings.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department recognises the importance of supporting and maintaining children’s right to play in healthcare settings. Games and active play in all settings build social skills and promote children’s well-being.
To support this, in June 2025 NHS England and Starlight, a national charity for children’s play in healthcare, co-published the Play Well Toolkit. The toolkit provides guidance on best practice, and includes a checklist to support the auditing, monitoring, and evaluation of services. NHS England is promoting the Play Well toolkit to managers of health play services across a wide range of settings, including community clinics, emergency departments, children’s hospices, and acute paediatric wards.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 October to Question 77603 on Brain: Tumours, what steps he plans to take to incentivise pharmaceutical companies involved in developing vaccines for brain tumours to approach the NHS Cancer Vaccine Launch Pad for funding and support.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). In the financial year 2024/25, the NIHR’s reported spend on cancer research was over £141.6 million through its research programmes and infrastructure, reflecting cancer’s high priority.
The Government is taking measures to boost research into brain tumours. In December 2025, the NIHR announced the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. NIHR is investing an initial £13.7 million with significant further funding due to be awarded in 2026.
We also support the Rare Cancers Private Members Bill. This bill aims to incentivise research and investment into treatment by introducing measures to streamline clinical trial recruitment, allow patients to be more easily contacted by researchers, and also mandates a review of orphan drug regulations.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including brain tumours. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his department is taking to improve (a) awareness, (b) diagnosis and (c) treatment for, pulmonary hypertension.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England commissions specialist services for both adults and children to diagnose and treat pulmonary arterial hypertension. Care is provided through a small number of specialised centres and shared care arrangements with other centres.
High-cost drug treatments are delivering improvements in outcomes for this group of patients, as evidenced by the National Pulmonary Hypertension Audit. This audit is funded by NHS England, with further information available at the following link:
Clinical guidelines and pathways exist for the investigation of breathlessness, to support the recognition and diagnosis of this rare condition.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 13 October to Question 77605 on Health Professions: Regulation, on what date he will publish a consultation on secondary legislation to modernise the General Medical Council’s regulatory framework which would enable them to consider fitness to practise concerns arising from allegations of sexual misconduct that are more than five years old.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Government is committed to modernising the regulatory frameworks for all healthcare professionals in the United Kingdom.
We aim to consult on secondary legislation to modernise the General Medical Council’s regulatory framework in early 2026 and to lay this legislation before Parliament in the same year. The Government will confirm a date for the public consultation in due course.
We also plan to update the governing legislation for the Nursing and Midwifery Council and the Health and Care Professions Council within the current parliamentary period.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 27 October 2025 to Question 77609 on Medical Treatments: Cost Effectiveness, if he will instruct NICE to review the adequacy of the Quality-Adjusted Life Year threshold for innovative medicines.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The pharmaceutical sector and the innovative medicines it produces are critical to our national interest, helping people access life changing treatments, reducing pressure on the health service over the longer-term, and ensuring we have a National Health Service that is fit for the future.
That is why through our Life Sciences Sector Plan, we have committed to working with industry to accelerate growth in spending on innovative medicines, compared to the previous decade. Our 10-Year Health Plan set out how we’d reform National Institute for Health and Care Excellence.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment as part of the New Hospital Programme of the adequacy of the number of helipads available for air ambulance use.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The clinical need and business cases for helipads at New Hospital Programme schemes will continue to be reviewed as schemes’ business plans progress through the usual assurance processes. As part of the Hospital 2.0 standardisation work, we are continuing to assess the advantages and disadvantages of both rooftop and ground-level helipads for inclusion in new hospital designs.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 27 May to Question 51941 on Paraneoplastic Encephalomyelitis: Diagnosis, if his Department will write to the laboratories that do provide testing for the condition and ask whether they provide testing for KLHL11 antibodies.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
There are no current plans to write to laboratories that provide testing for paraneoplastic encephalomyelitis to ask whether this includes KLHl11 antibody testing.
27 pathology networks across England are working to provide a vast range of tests to ensure the accurate and timely diagnosis of conditions. This includes those tests that are typically used to support the diagnosis of paraneoplastic encephalomyelitis, such as immunology tests.
The Government is supporting pathology networks to increase digital capabilities by March 2026 to reduce unnecessary waits and repeat tests, to ensure that patients receive their results sooner. This is supported by £600 million of capital in 2025/26 for diagnostics. This investment also provides funding for the automation of histopathology laboratories.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 27 October 2025 to Question 77609 on Medical Treatments: Cost Effectiveness, what percentage of completed NICE appraisals for brain tumour medications have led to approval for use of a medication by the NHS in the last 12 months.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) has not published final guidance on any brain tumour appraisals in the last 12 months.
NICE is currently developing guidance on the use of vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over and recently consulted on its draft recommendations. NICE currently expects to publish final guidance in January 2026.